Tweet

Session 702
Big Pharma Big Pharma M&A and Alliance Portfolios: What's at the end of the rainbow? and Alliance Portfolios: What's at the end of the rainbow?

The most recent decade in big pharma was marked by a dizzying array of deals, mergers, and acquisitions. Companies of all sizes have participated in the deal-making, including some of the biggest names in the industry. In virtually all cases, acquisition of technologies, platforms, and assets was a key driver for the transaction.

Additionally, many of these deals have included assets or technologies that were involved in formal alliances in one way or another. For transactions involving the acquisition or merger of large-cap biopharma companies, whole portfolios of alliances across multiple therapeutic areas, stages of development, and commercial geographies have been involved. Though not necessarily the top strategic driver for specific acquisitions, alliance portfolios should be viewed as containing value that is unique and different from the sum total of each individual alliance.

These four long-time ASAP members will share their recent M&A experiences and provide insight into how portfolios of alliances have been managed through the transaction process and engage participants in sharing additional perspectives critical for unlocking and maximizing the full value of an alliance portfolio. Key takeaways include:

Moderator:

Adam Kornetsky
Consultant
Vantage Partners

 

 

 

Panelists:

Mark Coflin, CSAP
Vice President Head of Global Alliances
Takeda Pharmaceuticals

 

 

 

 

 

Dana Hughes
Vice President of Integration Management and Alliance Management
Pfizer

 

 

 

Jeffrey C. Hurley
Senior Director, GBD Global Alliance Management Lead

Jeff is a recent employee of Shire and Takeda, joining the company in January 2018. Prior to Takeda, Jeff spent over 28 years with Eli Lilly and Company in a variety of roles and locations. Jeff has been in the Alliance Management function since 2008, and with Takeda has managed multiple discovery, development, and commercial alliances that span diverse therapeutic areas in Rare Diseases, Hematology, Neuroscience, and GI.

Currently, Jeff supports a number of commercial alliances and licenses, highlighted by the Trintellix alliance with Lundbeck.

At Lilly, Jeff supported alliances and collaborations in Lilly's innovative Device, Delivery, and Connected Systems organization as well as several commercial alliances, including partnerships with Sanofi, GSK, Kowa Company Ltd., Torii Pharmaceuticals, United Therapeutics, and Janssen Biotech.

Prior to his role in Alliance Management, Jeff held several leadership roles in operations, sales, marketing, disease management, and new product planning.

Jeff earned a bachelor's degree in Government from Dartmouth College, and an MBA from the University of Michigan.

Christopher Urban
Executive Director, Alliance Management & Integration
Amgen

Chris joined Amgen 12 years ago and currently leads the Alliance Management and Integration functions within Amgen's Business Development Organization. Chris' group leads alliances with partners that range from early stage technology/platforms through to commercial products, and includes both in-licensed and out-licensed products. He also leads the Integration Management Office for all acquisitions. Chris' previous roles at Amgen include Head of the External Process Development group, Oncology Operations Therapeutic Area Head, Global Operations Leader for Kyprolis, API Site Head at Amgen's Turkish affiliate Mustafa Nevzat, and various roles within Supply Chain and Quality.

Prior to Amgen, Chris ran the Chicago Operations hub for YRC Worldwide, started and sold a construction technology company, and served as officer in the US Navy Submarine Force. He holds an MBA in Finance from Vanderbilt's Owen Graduate School of Management and a BA in Economics and German from Vanderbilt University.